FDC (NSE:FDC) Institutional Ownership : 8.49% (As of Jun. 22, 2024)

View and export this data going back to 1997. Start your Free Trial

What is FDC Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, FDC's institutional ownership is 8.49%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, FDC's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, FDC's Float Percentage Of Total Shares Outstanding is 0.00%.

FDC Institutional Ownership Historical Data

The historical data trend for FDC's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

FDC Institutional Ownership Chart

FDC Historical Data

The historical data trend for FDC can be seen below:

	2023-08-31	2023-09-30	2023-10-31	2023-11-30	2023-12-31	2024-01-31	2024-02-29	2024-03-31	2024-04-30	2024-05-31
Institutional Ownership	9.59	9.35	9.28	9.12	9.08	8.52	8.26	8.32	8.36	8.49

FDC Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

FDC (NSE:FDC) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » FDC Ltd (NSE:FDC) » Definitions » Institutional Ownership

Traded in Other Exchanges

531599:India

Address

C-3 Skyvistas, Near Versova Police Station, D.N. Nagar, Andheri (West), Mumbai, MH, IND, 400053

Website

https://www.fdcindia.com

FDC Ltd is an Indian-based pharmaceutical company with USFDA and UK-MHRA-approved API and formulations manufacturing facilities. It has its presence in numerous therapeutic segments: Anti-infectives, Gastro-Intestinal, Vitamins/Minerals/Nutrients, Ophthalmology/Otologicals, Cardiac, Dermatology, Respiratory, Gynaecology, and Others. The company's brands include Zifi, Electral, Enerzal, Vitcofol, Pyrimon, Zocon, Zoxan, Zathrin, Zipod, Zefu, Cotaryl, and Mycoderm. The majority of the revenue is generated domestically.